| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802734201016 | 273420101 | TYSABRI C/S.SOL.IN 300MG/VIAL (20MG/ML) BT x 1 VIAL x 15 ML | 1162.93 | 1180.38 | 1313.76 |
For treatment of multiple sclerosis.
Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
11 ± 4 days
* 5.7 ± 1.9 L [Multiple Sclerosis (MS) Patients] * 5.2 ± 2.8 L [Crohn's Disease (CD) Patients]
* 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose] * 22 +/- 22 mL/hour [Patients with Crohn's Disease receiving the repeat IV administration of a 300 mg dose]